Achillion Pharmaceuticals (ACHN) 10.89 $ACHN
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:26AM CST
Acorda Therapeutics's (ACOR) fourth quarter earnings of 33 cents per share surpassed the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ACHN: 10.89 (-0.20), ACOR: 36.14 (-0.51)
Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:22AM CST
Ironwood Pharmaceuticals (IRWD) reported a loss of 27 cents per share in the fourth quarter of 2014, wider than the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), ACHN: 10.89 (-0.20)
AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:30PM CST
AbbVie (ABBV) filed a new drug application with the Japanese Ministry of Health, Labour and Welfare for its experimental, all-oral, ribavirin and interferon free hepatitis C virus treatment.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00)
Hospira Beats on Q4 Earnings, Set to Be Acquired by Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 9:28AM CST
Hospira's fourth-quarter 2014 adjusted earnings of 53 cents per share easily beat the Zacks Consensus Estimate of 41 cents.
ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20), PFE: 34.64 (-0.23), HSP: 87.35 (unch)
Achillion prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 5:54AM CST
ACHN: 10.89 (-0.20)
Achillion Pharmaceuticals prices public offering of 12m common stock
M2 - Thu Feb 12, 5:01AM CST
Pharmaceutical company Achillion Pharmaceuticals (NasdaqGS:ACHN) revealed on Wednesday that it has priced a public offering of 12,000,000 shares of its common stock.
ACHN: 10.89 (-0.20)
Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Feb 11, 10:59PM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $10.25 per share. All of the shares in the offering will be sold by Achillion. The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $115.3 million. The offering is expected to close on February 18, 2015, subject to customary closing conditions. Leerink Partners LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers, Wells Fargo Securities, LLC is acting as lead manager, and JMP Securities LLC is acting as co-manager for the offering.
ACHN: 10.89 (-0.20), WFC: 55.33 (+0.47)
Celgene Up on Abraxane Getting Positive Recommendation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 3:59PM CST
Celgene Corporation (CELG) was up 1.7% after the company announced that Abraxane has received a positive recommendation from the Scottish Medicines Consortium.
ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20), LLY: 70.56 (+0.03), CELG: 115.88 (+0.16)
Gilead Sciences Shares Rise Amid Insider Buy, Conference Presentation Broadcast - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Wed Feb 11, 3:38PM CST
Gilead Sciences was yet again in the news, this time following an insider buy, and biotech conferences.
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20)
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 11, 10:47AM CST
The hepatitis C virus (HCV) market remains in focus with Achillion (ACHN) presenting encouraging data.
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), REGN: 402.40 (+0.66), XNPT: 6.69 (-0.21), CELG: 115.88 (+0.16)
Zoetis Beats on Q4 Earnings, Provides In-Line 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:56AM CST
Zoetis' fourth-quarter 2014 adjusted earnings of 40 cents per share were ahead of the Zacks Consensus Estimate.
ZTS: 45.46 (-0.33), ABT: 46.09 (+0.87), ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20)
Critical Alerts For Transocean, Crane, Achillion Pharmaceuticals, Endocyte and Monster Beverage Released By InvestorsObserver
PR Newswire - Wed Feb 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for RIG, CR, ACHN, ECYT and MNST.
MNST: 117.74 (-1.77), ECYT: 5.26 (-0.02), RIG: 19.05 (+0.42), ACHN: 10.89 (-0.20), CR: 68.19 (-0.40)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:13AM CST
FCEL: 1.31 (unch), ADXS: 7.18 (+0.06), JONE: 10.18 (+0.18), INXN: 32.04 (+0.14), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), GNW: 8.67 (+0.17), WBAI: 17.36 (-0.30), PME: 2.42 (-0.07), RAD: 8.34 (+0.25), BLDP: 2.66 (-0.26), BXE: 2.79 (+0.05), PXD: 157.85 (+9.71), ACHN: 10.89 (-0.20), SDR: 4.66 (+0.10), LGF: 32.17 (+0.08), PIR: 12.52 (+0.17), AOL: 41.78 (+1.22), GNRC: 49.89 (+0.29), GOL: 3.85 (+0.01), DCTH: 1.14 (+0.04), CHS: 18.38 (+0.10)
Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price
at The Street - Wed Feb 11, 8:04AM CST
Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00)
'Mad Money' Lightning Round: Stop Fretting and Buy, Buy, Buy Sirius XM
at The Street - Wed Feb 11, 5:00AM CST
Cramer says stick with Taser and take UnitedHealth or Humana over HMS Holdings.
BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), TASR: 26.96 (-0.42), HMSY: 20.00 (+0.38), SIRI: 3.83 (-0.07), REGN: 402.40 (+0.66), HUM: 152.67 (-1.06), CELG: 115.88 (+0.16)
Achillion Pharmaceuticals plans to launch public offering of 10m common shares
M2 - Wed Feb 11, 4:53AM CST
Pharmaceutical company Achillion Pharmaceuticals (NasdaqGS:ACHN) reported on Tuesday that it has commenced a public offering of 10,000,000 shares of its common stock.
ACHN: 10.89 (-0.20)
Baxter Needs To Split Up - Cramer's Lightning Round (2/10/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Wed Feb 11, 4:28AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, February 10. Bullish Calls: Achillion Pharmaceuticals (NASDAQ: ACHN ): " We have said it's a decent spec off of another Hep C," said Cramer....
CI: 114.47 (-0.51), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HMSY: 20.00 (+0.38), TASR: 26.96 (-0.42), SIRI: 3.83 (-0.07), REGN: 402.40 (+0.66), HUM: 152.67 (-1.06), CELG: 115.88 (+0.16)
Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News
at The Street - Tue Feb 10, 7:35PM CST
With no distractions, the U.S stock market rallied on a slew of terrific company news.
BIIB: 391.66 (-0.45), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HOT: 78.55 (+0.67), HUM: 152.67 (-1.06), SBUX: 91.58 (-0.24), SAVE: 79.32 (-0.80), MAT: 27.61 (+0.17), CMG: 674.89 (+4.60), TASR: 26.96 (-0.42), REGN: 402.40 (+0.66), SIRI: 3.83 (-0.07), KO: 41.99 (-0.18), HAS: 62.74 (+0.58), DIS: 104.17 (+0.59), ALKS: 71.40 (-1.89), MAS: 26.45 (+0.02), ARO: 3.63 (+0.04), CELG: 115.88 (+0.16), URBN: 38.47 (+0.27), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), GM: 37.62 (-0.40), YELP: 47.53 (-0.10), HMSY: 20.00 (+0.38)
Most active Nasdaq-traded stocks
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.86 (-0.22), MU: 31.85 (-0.09), FTR: 8.38 (+0.01), AMD: 3.15 (+0.03), ANTH: 3.84 (+0.06), ACHN: 10.89 (-0.20), ODP: 9.59 (-0.02), MSFT: 43.87 (+0.78), INTC: 34.36 (+0.23), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:26AM CST
Acorda Therapeutics's (ACOR) fourth quarter earnings of 33 cents per share surpassed the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ACHN: 10.89 (-0.20), ACOR: 36.14 (-0.51)
Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:22AM CST
Ironwood Pharmaceuticals (IRWD) reported a loss of 27 cents per share in the fourth quarter of 2014, wider than the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), ACHN: 10.89 (-0.20)
AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:30PM CST
AbbVie (ABBV) filed a new drug application with the Japanese Ministry of Health, Labour and Welfare for its experimental, all-oral, ribavirin and interferon free hepatitis C virus treatment.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00)
Hospira Beats on Q4 Earnings, Set to Be Acquired by Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 9:28AM CST
Hospira's fourth-quarter 2014 adjusted earnings of 53 cents per share easily beat the Zacks Consensus Estimate of 41 cents.
ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20), PFE: 34.64 (-0.23), HSP: 87.35 (unch)
Achillion prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 5:54AM CST
ACHN: 10.89 (-0.20)
Achillion Pharmaceuticals prices public offering of 12m common stock
M2 - Thu Feb 12, 5:01AM CST
Pharmaceutical company Achillion Pharmaceuticals (NasdaqGS:ACHN) revealed on Wednesday that it has priced a public offering of 12,000,000 shares of its common stock.
ACHN: 10.89 (-0.20)
Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Feb 11, 10:59PM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $10.25 per share. All of the shares in the offering will be sold by Achillion. The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $115.3 million. The offering is expected to close on February 18, 2015, subject to customary closing conditions. Leerink Partners LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers, Wells Fargo Securities, LLC is acting as lead manager, and JMP Securities LLC is acting as co-manager for the offering.
ACHN: 10.89 (-0.20), WFC: 55.33 (+0.47)
Celgene Up on Abraxane Getting Positive Recommendation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 3:59PM CST
Celgene Corporation (CELG) was up 1.7% after the company announced that Abraxane has received a positive recommendation from the Scottish Medicines Consortium.
ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20), LLY: 70.56 (+0.03), CELG: 115.88 (+0.16)
Gilead Sciences Shares Rise Amid Insider Buy, Conference Presentation Broadcast - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Wed Feb 11, 3:38PM CST
Gilead Sciences was yet again in the news, this time following an insider buy, and biotech conferences.
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20)
Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 11, 10:47AM CST
The hepatitis C virus (HCV) market remains in focus with Achillion (ACHN) presenting encouraging data.
GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), REGN: 402.40 (+0.66), XNPT: 6.69 (-0.21), CELG: 115.88 (+0.16)
Zoetis Beats on Q4 Earnings, Provides In-Line 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:56AM CST
Zoetis' fourth-quarter 2014 adjusted earnings of 40 cents per share were ahead of the Zacks Consensus Estimate.
ZTS: 45.46 (-0.33), ABT: 46.09 (+0.87), ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20)
Critical Alerts For Transocean, Crane, Achillion Pharmaceuticals, Endocyte and Monster Beverage Released By InvestorsObserver
PR Newswire - Wed Feb 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for RIG, CR, ACHN, ECYT and MNST.
MNST: 117.74 (-1.77), ECYT: 5.26 (-0.02), RIG: 19.05 (+0.42), ACHN: 10.89 (-0.20), CR: 68.19 (-0.40)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:13AM CST
FCEL: 1.31 (unch), ADXS: 7.18 (+0.06), JONE: 10.18 (+0.18), INXN: 32.04 (+0.14), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), GNW: 8.67 (+0.17), WBAI: 17.36 (-0.30), PME: 2.42 (-0.07), RAD: 8.34 (+0.25), BLDP: 2.66 (-0.26), BXE: 2.79 (+0.05), PXD: 157.85 (+9.71), ACHN: 10.89 (-0.20), SDR: 4.66 (+0.10), LGF: 32.17 (+0.08), PIR: 12.52 (+0.17), AOL: 41.78 (+1.22), GNRC: 49.89 (+0.29), GOL: 3.85 (+0.01), DCTH: 1.14 (+0.04), CHS: 18.38 (+0.10)
Achillion: Hep C Drug Discounting May Hurt Our Market Value, Stock Price
at The Street - Wed Feb 11, 8:04AM CST
Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night.
ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), CVS: 102.63 (-0.37), ABBV: 58.05 (+1.00)
'Mad Money' Lightning Round: Stop Fretting and Buy, Buy, Buy Sirius XM
at The Street - Wed Feb 11, 5:00AM CST
Cramer says stick with Taser and take UnitedHealth or Humana over HMS Holdings.
BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), TASR: 26.96 (-0.42), HMSY: 20.00 (+0.38), SIRI: 3.83 (-0.07), REGN: 402.40 (+0.66), HUM: 152.67 (-1.06), CELG: 115.88 (+0.16)
Achillion Pharmaceuticals plans to launch public offering of 10m common shares
M2 - Wed Feb 11, 4:53AM CST
Pharmaceutical company Achillion Pharmaceuticals (NasdaqGS:ACHN) reported on Tuesday that it has commenced a public offering of 10,000,000 shares of its common stock.
ACHN: 10.89 (-0.20)
Baxter Needs To Split Up - Cramer's Lightning Round (2/10/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Wed Feb 11, 4:28AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, February 10. Bullish Calls: Achillion Pharmaceuticals (NASDAQ: ACHN ): " We have said it's a decent spec off of another Hep C," said Cramer....
CI: 114.47 (-0.51), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HMSY: 20.00 (+0.38), TASR: 26.96 (-0.42), SIRI: 3.83 (-0.07), REGN: 402.40 (+0.66), HUM: 152.67 (-1.06), CELG: 115.88 (+0.16)
Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News
at The Street - Tue Feb 10, 7:35PM CST
With no distractions, the U.S stock market rallied on a slew of terrific company news.
BIIB: 391.66 (-0.45), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HOT: 78.55 (+0.67), HUM: 152.67 (-1.06), SBUX: 91.58 (-0.24), SAVE: 79.32 (-0.80), MAT: 27.61 (+0.17), CMG: 674.89 (+4.60), TASR: 26.96 (-0.42), REGN: 402.40 (+0.66), SIRI: 3.83 (-0.07), KO: 41.99 (-0.18), HAS: 62.74 (+0.58), DIS: 104.17 (+0.59), ALKS: 71.40 (-1.89), MAS: 26.45 (+0.02), ARO: 3.63 (+0.04), CELG: 115.88 (+0.16), URBN: 38.47 (+0.27), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), GM: 37.62 (-0.40), YELP: 47.53 (-0.10), HMSY: 20.00 (+0.38)
Most active Nasdaq-traded stocks
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.86 (-0.22), MU: 31.85 (-0.09), FTR: 8.38 (+0.01), AMD: 3.15 (+0.03), ANTH: 3.84 (+0.06), ACHN: 10.89 (-0.20), ODP: 9.59 (-0.02), MSFT: 43.87 (+0.78), INTC: 34.36 (+0.23), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03)
